RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Joe Ramos to Humans

This is a "connection" page, showing publications Joe Ramos has written about Humans.
Connection Strength

0.373
  1. Shi GX, Yang WS, Jin L, Matter ML, Ramos JW. RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases. Proc Natl Acad Sci U S A. 2018 01 09; 115(2):E190-E199.
    View in: PubMed
    Score: 0.029
  2. Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW. RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget. 2016 Nov 29; 7(48):79869-79884.
    View in: PubMed
    Score: 0.027
  3. Sulzmaier FJ, Ramos JW. RSK isoforms in cancer cell invasion and metastasis. Cancer Res. 2013 Oct 15; 73(20):6099-105.
    View in: PubMed
    Score: 0.022
  4. Gawecka JE, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Heikkil? MM, Matter ML, Ramos JW. RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration. J Biol Chem. 2012 Dec 21; 287(52):43424-37.
    View in: PubMed
    Score: 0.020
  5. Sulzmaier FJ, Li Z, Nakashige ML, Fash DM, Chain WJ, Ramos JW. Englerin a selectively induces necrosis in human renal cancer cells. PLoS One. 2012; 7(10):e48032.
    View in: PubMed
    Score: 0.020
  6. Sulzmaier F, Opoku-Ansah J, Ramos JW. Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter. Small GTPases. 2012 Jul-Sep; 3(3):173-7.
    View in: PubMed
    Score: 0.020
  7. Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer. 2012 Oct 01; 131(7):1556-68.
    View in: PubMed
    Score: 0.019
  8. Sulzmaier FJ, Valmiki MK, Nelson DA, Caliva MJ, Geerts D, Matter ML, White EP, Ramos JW. PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D. Oncogene. 2012 Jul 26; 31(30):3547-60.
    View in: PubMed
    Score: 0.019
  9. Pastorino S, Renganathan H, Caliva MJ, Filbert EL, Opoku-Ansah J, Sulzmaier FJ, Gawecka JE, Werlen G, Shaw AS, Ramos JW. The death effector domain protein PEA-15 negatively regulates T-cell receptor signaling. FASEB J. 2010 Aug; 24(8):2818-28.
    View in: PubMed
    Score: 0.017
  10. Valmiki MG, Ramos JW. Death effector domain-containing proteins. Cell Mol Life Sci. 2009 Mar; 66(5):814-30.
    View in: PubMed
    Score: 0.016
  11. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008; 40(12):2707-19.
    View in: PubMed
    Score: 0.015
  12. Pastorino S, Ramos JW. Glioma: challenges and new insights in the development of effective therapies. Hawaii Med J. 2008 Jan; 67(1):20-3, 25.
    View in: PubMed
    Score: 0.015
  13. Vaidyanathan H, Opoku-Ansah J, Pastorino S, Renganathan H, Matter ML, Ramos JW. ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19837-42.
    View in: PubMed
    Score: 0.014
  14. Renganathan H, Vaidyanathan H, Knapinska A, Ramos JW. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem J. 2005 Sep 15; 390(Pt 3):729-35.
    View in: PubMed
    Score: 0.012
  15. Sur R, Ramos JW. Vanishin is a novel ubiquitinylated death-effector domain protein that blocks ERK activation. Biochem J. 2005 Apr 15; 387(Pt 2):315-24.
    View in: PubMed
    Score: 0.012
  16. Ramos JW. Cancer research center hotline: PEA-15 phosphoprotein: a potential cancer drug target. Hawaii Med J. 2005 Mar; 64(3):77-80.
    View in: PubMed
    Score: 0.012
  17. Vaidyanathan H, Ramos JW. RSK2 activity is regulated by its interaction with PEA-15. J Biol Chem. 2003 Aug 22; 278(34):32367-72.
    View in: PubMed
    Score: 0.011
  18. Ramos JW, Hughes PE, Renshaw MW, Schwartz MA, Formstecher E, Chneiweiss H, Ginsberg MH. Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion-independent mechanism. Mol Biol Cell. 2000 Sep; 11(9):2863-72.
    View in: PubMed
    Score: 0.009
  19. Greig FH, Kennedy S, Gibson G, Ramos JW, Nixon GF. PEA-15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective Mediator in the Vasculature and Is Regulated During Neointimal Hyperplasia. J Am Heart Assoc. 2017 Sep 11; 6(9).
    View in: PubMed
    Score: 0.007
  20. Doe J, Kaindl AM, Jijiwa M, de la Vega M, Hu H, Griffiths GS, Fontelonga TM, Barraza P, Cruz V, Van Ry P, Ramos JW, Burkin DJ, Matter ML. PTRH2 gene mutation causes progressive congenital skeletal muscle pathology. Hum Mol Genet. 2017 04 15; 26(8):1458-1464.
    View in: PubMed
    Score: 0.007
  21. Jorand R, Biswas S, Wakefield DL, Tobin SJ, Golfetto O, Hilton K, Ko M, Ramos JW, Small AR, Chu P, Singh G, Jovanovic-Talisman T. Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer. Mol Biol Cell. 2016 11 07; 27(22):3659-3672.
    View in: PubMed
    Score: 0.007
  22. Fash DM, Peer CJ, Li Z, Talisman IJ, Hayavi S, Sulzmaier FJ, Ramos JW, Sourbier C, Neckers L, Figg WD, Beutler JA, Chain WJ. Synthesis of a stable and orally bioavailable englerin analogue. Bioorg Med Chem Lett. 2016 06 01; 26(11):2641-4.
    View in: PubMed
    Score: 0.006
  23. Liang Z, Sulzmaier FJ, Yoshida WY, Kelly M, Ramos JW, Williams PG. Neopetrocyclamines A and B, polycyclic diamine alkaloids from the sponge Neopetrosia cf exigua. J Nat Prod. 2015 Mar 27; 78(3):543-7.
    View in: PubMed
    Score: 0.006
  24. Frik M, Mart?nez A, Elie BT, Gonzalo O, Ram?rez de Mingo D, Sana? M, S?nchez-Delgado R, Sadhukha T, Prabha S, Ramos JW, Marzo I, Contel M. In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem. 2014 Dec 11; 57(23):9995-10012.
    View in: PubMed
    Score: 0.006
  25. Liang Z, Sorribas A, Sulzmaier FJ, Jim?nez JI, Wang X, Sauvage T, Yoshida WY, Wang G, Ramos JW, Williams PG. Stictamides A-C, MMP12 inhibitors containing 4-amino-3-hydroxy-5-phenylpentanoic acid subunits. J Org Chem. 2011 May 20; 76(10):3635-43.
    View in: PubMed
    Score: 0.005
  26. Griffiths GS, Grundl M, Leychenko A, Reiter S, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Ramos JW, Matter ML. Bit-1 mediates integrin-dependent cell survival through activation of the NFkappaB pathway. J Biol Chem. 2011 Apr 22; 286(16):14713-23.
    View in: PubMed
    Score: 0.005
  27. Hunter I, Mascall KS, Ramos JW, Nixon GF. A phospholipase C?1-activated pathway regulates transcription in human vascular smooth muscle cells. Cardiovasc Res. 2011 Jun 01; 90(3):557-64.
    View in: PubMed
    Score: 0.005
  28. Gawecka JE, Griffiths GS, Ek-Rylander B, Ramos JW, Matter ML. R-Ras regulates migration through an interaction with filamin A in melanoma cells. PLoS One. 2010 Jun 23; 5(6):e11269.
    View in: PubMed
    Score: 0.004
  29. Renault-Mihara F, Beuvon F, Iturrioz X, Canton B, De Bouard S, L?onard N, Mouhamad S, Sharif A, Ramos JW, Junier MP, Chneiweiss H. Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism. Mol Biol Cell. 2006 Dec; 17(12):5141-52.
    View in: PubMed
    Score: 0.003
  30. Zhang Y, Redina O, Altshuller YM, Yamazaki M, Ramos J, Chneiweiss H, Kanaho Y, Frohman MA. Regulation of expression of phospholipase D1 and D2 by PEA-15, a novel protein that interacts with them. J Biol Chem. 2000 Nov 10; 275(45):35224-32.
    View in: PubMed
    Score: 0.002
  31. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature. 1997 Nov 06; 390(6655):81-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support